01 January 1998
LDL-apheresis and its effects on the lipid profile and plasma fibrinogen level in patients with refractory hypercholesterolemia-preliminary report
Ewa Konduracka, Wiesława Piwowarska, Aldona Dembińska-Kieć, Stanisław Bartuś, Łukasz Partyka, Jadwiga Hartwich, Iwona Gołąbek, Izabella Pietrzak, Jerzy Sadowski, Dariusz DudekMed Sci Monit 1998; 4(6): CR938-941 :: ID: 451727
Abstract
LDL-apheresis is a method for the extracorporeal removal of LDL-cholesterol and its modified forms in patients with refractory hypercholesterolemia, who are unresponsive towards standard lipid lowering diets as well as drugs. The aim of this study was to analyse the influence of LDL apheresis on blood lipid profile and plasma fibrinogen concentration changes in patients with ischemic heart disease and refractory hypercholesterolemia. The study group comprised six men, aged between 39-54 who underwent coronary angiography and invasive treatment (3-PTCA, 3-CABG). The patients mean total cholesterol level was 7.7 mmol/l and the mean LDL-cholesterol level was 5.7 mmol/l despite a diet and one months treatment with simvastatine (20- 40mg/day). The mean plasma fibrinogen level prior to apheresis was 3.7g/l. Treatment with LDL-apheresis was introduced, two days before the revascularization procedure and continued for a period of one to three months following PTCA or CABG, in order to maintain the LDL-cholesterol level below 2.5 mmol/l. Results: A single LDL apheresis caused reduction of the mean total cholesterol level by 53% and mean LDL-cholesterol level by 65%. Examination of the LDL fraction revealed an increase of resistance towards oxidation performed ex vivo. We also observed a transient decrease in the mean plasma fibrinogen level (by 21%). Conclusions: LDL apheresis is a safe and effective method in the treatment of refractory hypercholesterolemia. Continued therapy with LDL-apheresis decreases coronary artery disease risk factors such as hypercholesterolemia and hyperfibrinogenemia.
Keywords: LDL-apheresis, refractory hypercholesterolemia
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
26 Feb 2024 : Clinical Research
Predictive Value of Combined HbA1c and Neutrophil-to-Lymphocyte Ratio for Diabetic Peripheral Neuropathy in...Med Sci Monit In Press; DOI: 10.12659/MSM.942509
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952